Consensus on the use of substituted benzamides in psychiatric patients

Neuropsychobiology

Volumn 50, Issue 2, 2004, Pages 134-143

  Racagni, Giorgio ^a   Canonico, Pier Luigi ^b   Ravizza, Luigi ^c   Pani, Luca ^d   Amore, Mario ^e  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d CNR   (Italy)

^e UNIVERSITY OF PARMA   (Italy)

Author keywords

Amisulpride; Depression; Dopaminergic receptors; Dysthymia; Schizophrenia; Substituted benzamides

Indexed keywords

AMINEPTINE; AMISULPRIDE; AMITRIPTYLINE; BENZAMIDE DERIVATIVE; CLOZAPINE; FLUOXETINE; FLUPHENAZINE; HALOPERIDOL; IMIPRAMINE; OLANZAPINE; PAROXETINE; QUETIAPINE; RISPERIDONE; SERTRALINE; ZOTEPINE;

BRAIN REGION; CHRONIC DISEASE; CLINICAL TRIAL; CONSENSUS; DEPRESSION; DOPAMINERGIC TRANSMISSION; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG UTILIZATION; DYSMENORRHEA; DYSTHYMIA; EXPERIMENT; EXTRAPYRAMIDAL SYMPTOM; GYNECOMASTIA; HUMAN; HYPERPROLACTINEMIA; IMPOTENCE; MENSTRUATION DISORDER; MENTAL PATIENT; NEUROLOGIC DISEASE; PARKINSONISM; PRIORITY JOURNAL; RATING SCALE; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; STRUCTURE ANALYSIS; SYNDROME;

ANTIPSYCHOTIC AGENTS; BENZAMIDES; DEPRESSIVE DISORDER; HUMANS; MENTAL DISORDERS; SCHIZOPHRENIA; SULPIRIDE;

EID: 4043055295     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000079104     Document Type: Review

References (49)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4 (DSM-IV). Washington, American Psychiatric Association, 1994.
2. Amore M, Jori MC, AMISERT Investigators: Faster response on amisulpride 50 mg versus sertraline 50-100 mg in patient with dysthymia or double depression: A randomized doubleblind, parallel group study. Int Clin Psychopharmacol 2001;16:317-324.
3. Boyer P, Lecrubier Y, Puech J: Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry 1995;166:68-72.
4. Boyer P, Lecrubier Y, Stalla-Bourdillon A, Fleurot O: Amisulpride versus amineptine and placebo for the treatment of dysthymia. Neuropsychobiology 1999;39:25-32.
5. Carrière P, Bonhomme D, Lempeirere T: Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: Results of a multicentre, double-blind study. The Amisulpride Study Group. Eur Psychiatry 2000;15:321-329.
6. Cassano GB, Jori MC: Efficacy and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression: A randomised, double-blind, parallel group study. Int Clin Psychopharmacol 2002;17:27-32.
7. Colonna L, Saleem P, Dondey-Nouvel L: Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. Int Clin Psychopharmacol 2000;15:13-22.
8. Costa e Silva JA: Comparative double-blind study of amisulpride vs haloperidol in the treatment of acute psychotic state; in Borenstein et al (eds): Amisulpride. Paris, Expansion Scientifique Française, 1989.
9. Danion JM, Rein W, Fleurot O: Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group. Am J Psychiatry 1999;156:610-616.
10. Davis, JM Chen N, Glick ID: A meta-analysis of the efficacy of second generation antipsychotics. Arch Gen Psychiatry 2003;60:553-564.
11. Green B: Focus on amisulpride. Curr Med Res Opin 2002;18:113-117.
12. Kasper S: Dopaminergic deficit and the role of amisulpride in the treatment of schizophrenia. Int Clin Psychopharmacol 2002;17(suppl 4):19-26.
13. Knapp M: An international comparison of health care resources utilisation: Amisulpride versus risperidone. Int J Neuropsychopharmacol 2002;5(suppl 1):S181-S182.
14. Lecrubier Y, Azorin M, Bottai T: Consensus on the practical use of amisulpride, an atypical antipsychotic, in the treatment of schizophrenia. Neuropsychobiology 2001;44:41-46.
15. Lecrubier Y, Boyer P, Turjanski S, Rein W: Amisulpride versus imipramine and placebo in dysthymia and major depression. J Affect Disord 1997;43:95-103.
16. Leucht S, Pitschel-Walts G, Engel RR, Kissling W: Amisulpride un unusual 'atypical' antipsycotic. A meta-analysis of randomized controlled studies. Am J Psychiatry 2002;159:180-190.
17. Loo H, Poirier-Littre MF, Theron M, Rein W, Fleurot O: Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry 1997;170:18-22.
18. Martin S, Loo H, Peuskens J: A double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: Short-term results at two months. Curr Med Res Opin 2002;18:355-362.
19. Moller HJ, Boyer P, Fleurot O, Rein W: Improvement of acute exacerbations of schizophrenia with amisulpride: A comparison with haloperidol. Psychopharmacology 1997;132:396-401.
20. Montgomery SA: Dopaminergic deficit and role of amisulpride in the treatment of mood disorders. Int Clin Psychopharmacol 2002;17(suppl 4):9-17.
21. Muller-Spahn F: Current use of atypical antipsychotics. Eur Psychiatry 2002;17(suppl 4):377-384.
22. National Institute for Clinical Excellence (NICE): Guidance on the Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. Technology Appraisal Guidance. London, NICE, 2002, No 43, pp 1-22.
23. Olie JP, Levy E, Carita P: Economic assessment of neuroleptic strategies in schizophrenia: Intermediate results of OASIS study. World J Biol Psychiatry 2001;2(suppl 1):308.
24. Paillère-Martinot ML, Lecrubier Y, Martinot JL, Aubin F: Improvement of some schizophrenic deficit symptoms with low doses of amisulpride Am J Psychiatry 1995;152:130-133.
25. Pani L, Gessa GL: The substituded benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia. Mol Psychiatry 2002;7:247-253.
26. Peuskens J, Bech P, Moller HJ, Bale R, Fleurot O, Rein W: Amisulpride vs risperidone in the treatment of acute exacerbations of schizophrenia. Psychiatry Res 1999;88:107-117.
27. Peuskens J, Moller HJ, Puech A: Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: Comparison with haloperidol and risperidone. Eur Neuropsychopharmacol 2002;12:305-310.
28. Pichot P, Boyer P: Essai multicentrique controlé en double insu, amisulpride (Solian 50) contre fluphenazine à faible dose dans le traitement du syndrome déficitaire des schizophrénies chroniques. Ann Psychiatry 1988a;3:312-320.
29. Pichot P, Boyer P: Etude multicentrique controlée en double insu amisulpride (Solian 200) versus halopéridol à forte dose dans les états psychotiques aigus. Ann Psychiatry 1988b;3:326-332.
30. Puech A, Fleurot O, Rein W: Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: A dose-ranging study vs haloperidol. Acta Psychiatr Scand 1998;98:65-72.
31. Ravizza L: Amisulpride in medium-term treatment of dysthymia: A six-month double-blind safety study versus amitriptyline. J Psychopharmacol 1999;13:248-254.
32. Saletu B, Kufferle B, Grunberger J, Foldes P, Topitz A, Anderer P: Clinical, EEG mapping and psychometric studies in negative schizophrenia: Comparative trials with amisulpride and fluphenazione. Neuropsychobiology 1994;29:125-135.
33. Scatton B, Claustre Y, Cudennec A: Amisulpride: From animal pharmacology to therapeutic action. Int Clin Psycopharmacol 1997;12(suppl 2):S29-S36.
34. 3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 1997;280:83-97.
35. Sechter D, Peuskens J, Fleurot O, Rein W, Lecrubier Y: Amisulpride vs risperidone in chronic schizophrenia: Results of a 6-month double-blind study. Neuropsychopharmacology 2002;27:1071-1081.
36. Seeman P: Atypical antipsychotics: Mechanism of action. Can J Psychiatry 2002;47:27-38.
37. Soutre E, Martin P, Lecanu JP: Economic assessment of neuroleptic strategies in schizophrenia. Encephale 1992;8:263-269.
38. Smeraldi E: Amisulpride versus fluoxetine in paients with dysthymia or major depression in partial remission. A double-blind, comparative study. J Affect Disord 1998;48:47-56.
39. Spano PF: Interazioni farmacologiche dei farmaci antidepressivi. G Neuropsicofarmacol 2000;5:3-20.
40. Speller JC, Barnes TR, Curson A, Pantelis C, Alberts JL: One-year low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Br J Psychiatry 1997;171:564-568.
41. Task Force of the World Psychiatric Association (WPA): The usefulness and use of second-generation antipsychotic medications. Curr Opin Psychiatry 2002;15(suppl 1):1-51.
42. Taylor AM, McAskill R: Atypical antipsychotics and weight gain - a systematic review. Acta Psychiatr Scand 2000;101:416-432.
43. Thome M, Zink U, Knopf FA: Combination of olanzapine and amisulpride in 'treatment-resistant' schizophrenic psychoses. Int J Neuropsychopharmacol 2002;5(suppl 1):S76.
44. Thornicroft C, Maingay S: The global response to mental illness. BMJ 2002;325:608-609.
45. 2-like antagonist. Psychopharmacology 1998;137:223-232.
46. World Health Organization: International Classification of Diseases, 10th Revision (ICD-10). Geneva, World Health Organization, 1992.
47. Ziegenbein M, Rosenthal O, Garlipp P: Coadministration of clozapine and amisulpride in psychotic patient. Int J Neuropsychopharmacol 2002;5(suppl 1):99s.
48. Ziegler B: Study of the efficacy of a substituted benzamide, amisulpride, versus haloperidol in productive schizophrenia; in Borenstein et al (eds): Amisulpride. Paris, Expansion Scientifique Française, 1989.
49. Del Zompo M: Safety of amisulpride over longterm administration: A 12-month, open study in patients with pure dysthymic disorder. Eur Neuropsychopharmacol 2002;12(suppl):S41.